Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo
Condition: Non-Segmental Vitiligo
Testing For: XCL1/2 (LY4005130)
Trial ID: J5D-MC-FPAD
Age: 18 to ≤75 years of age
Phase: 2
Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Severe Alopecia Areata
Condition: Severe Alopecia Areata
Testing For: XCL1/2 (LY4005130)
Trial ID: J5D-MC-FPAC
Age: 18 to ≤50 years of age
Phase: 2
EMERALD-3: A Phase 2b/3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis
Condition: Ulcerative Colitis
Testing for: LY4268989 (MORF-057)
Trial ID: J6E-MC-KWAM
Age: 18 - 80
Phase: 2 and 3
A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)
Condition: Ovarian Cancer
Testing for: LY4170156, mirvetuximab soravtansine, topotecan, bevacizumab, paclitaxel, carboplatin, gemcitabine
Trial ID: J5E-MC-JZXB
Age: ≥18 years
Phase: 3
FORAGER-2 Study: A clinical research study for people living with bladder cancer and a change in the FGFR3 gene
Condition: Bladder Cancer
A Study Investigating Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Trial ID: J4G-MC-JZVD
Age: ≥18 years
Phase: 3
TOPAZ-UC: A Phase 2, Multicenter, Randomized, Double-Blind, Active- Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
Condition: Ulcerative Colitis
Drugs: LY4268989 (MORF-057) and Mirikizumab (LY3074828)
Trial ID: J6E-MC-KWAN
Age: 18-80
Phase: 2
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight (COMMIT-CD)
Condition: Crohn’s Disease, Obesity
Drugs: Mirikizumab, Tirzepatide
Trial ID: I6T-MC-AMCE
Age: 18-70 years
Phase: 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC) Conditions the trial is for: Ulcerative Colitis, Obesity
Condition: Ulcerative Colitis, Obesity
Trial ID: I6T-MC-AMCD
Age: 18-70 Years old
Phase: 3
